Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Toyota Global Sales Fall as China Demand Slumps 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Add as a preferred source on Google
ANAHEIM, CA, April 09, 2018 -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, and legendary soul man Sam Moore appeared as guests on Fox Business Network’s Mornings with Maria this morning to discuss the company's naltrexone implant and how it helps combat opioid addiction.
"Mornings with Maria" features anchor Maria Bartiromo alongside a roundtable of rotating industry titans and economic experts discussing the major news and themes driving the business day and the market moves. You can view the segment here: https://www.foxbusiness.com/features/legendary-soul-man-sam-moore-backs-new-implant-to-treat-opioid-addiction.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. [email protected] 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 [email protected]
